Gene: SH3PXD2A

9644
FISH|SH3MD1|TKS5
SH3 and PX domains 2A
protein-coding
10q24.33
Ensembl:ENSG00000107957 Vega:OTTHUMG00000018997 UniprotKB:Q5TCZ1
NC_000010.11
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
6.857e-2 (AD)  3.904e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs12573437chr10:103843405 (GRCh38.p7)C>Aalcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg18735015chr10:105428506SH3PXD2AGene body5.664e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RAB11FIP40.915
VASH10.867
COBL0.864
ASB10.863
TTLL110.861
NIPAL30.852
PEX50.847
PKP40.828
TRAK20.825
DLG10.825

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F29-0.518
OR4F5-0.43
GJB2-0.342
PON3-0.332
DMRTA1-0.316
TMPRSS3-0.313
LYN-0.312
EGFLAM-0.297
HGF-0.296
ADORA2B-0.296

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0235142,6-dinitrotoluene"2,6-dinitrotoluene affects the expression of SH3PXD2A mRNA"21346803
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3PXD2A mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3PXD2A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3PXD2A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3PXD2A mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of SH3PXD2A mRNA26690555
D000082Acetaminophen[Clofibrate co-treated with Acetaminophen] affects the expression of SH3PXD2A mRNA17585979
D000082AcetaminophenPPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of SH3PXD2A mRNA]17585979
D016604Aflatoxin B1Aflatoxin B1 affects the expression of SH3PXD2A protein20106945
D001280AtrazineAtrazine results in decreased expression of SH3PXD2A mRNA25929836
C030935benz(a)anthracene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SH3PXD2A mRNA27858113
C006703benzo(b)fluoranthene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SH3PXD2A mRNA27858113
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SH3PXD2A mRNA20064835|2010694
D001564Benzo(a)pyrene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SH3PXD2A mRNA27858113
D004958EstradiolEstradiol results in decreased expression of SH3PXD2A mRNA20106945
C543008bis(4-hydroxyphenyl)sulfone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of SH3PXD2A mRNA28628672
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of SH3PXD2A mRNA28628672
C006780bisphenol Abisphenol A results in decreased expression of SH3PXD2A mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of SH3PXD2A mRNA29097150
C006780bisphenol Abisphenol A results in increased methylation of SH3PXD2A gene28505145
C018475butyraldehydebutyraldehyde results in decreased expression of SH3PXD2A mRNA26079696
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of SH3PXD2A gene20938992
C031180chrysene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SH3PXD2A mRNA27858113
D002922CiguatoxinsCiguatoxins affects the expression of SH3PXD2A mRNA18353800
D002994Clofibrate[Clofibrate co-treated with Acetaminophen] affects the expression of SH3PXD2A mRNA17585979
D002994ClofibratePPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of SH3PXD2A mRNA]17585979
D003033Coal TarCoal Tar results in decreased expression of SH3PXD2A mRNA27858113
D003300Copper[Disulfiram binds to Copper] which results in increased expression of SH3PXD2A mRNA24690739
D019327Copper SulfateCopper Sulfate results in decreased expression of SH3PXD2A mRNA19549813
D016572CyclosporineCyclosporine results in decreased expression of SH3PXD2A mRNA20106945
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of SH3PXD2A mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of SH3PXD2A mRNA28628672
D002945CisplatinCisplatin results in decreased expression of SH3PXD2A mRNA27392435
D002945CisplatinCisplatin results in increased phosphorylation of SH3PXD2A protein22006019
C000944dicrotophosdicrotophos results in increased expression of SH3PXD2A mRNA28302478
D002117CalcitriolCalcitriol results in decreased expression of SH3PXD2A mRNA26485663
D002117CalcitriolCalcitriol results in increased expression of SH3PXD2A mRNA16002434
D004221Disulfiram[Disulfiram binds to Copper] which results in increased expression of SH3PXD2A mRNA24690739
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of SH3PXD2A mRNA29097150
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in decreased expression of SH3PXD2A mRNA23649840
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of SH3PXD2A gene20938992
C069837fullerene C60fullerene C60 results in decreased expression of SH3PXD2A mRNA19167457
D017313FenretinideFenretinide results in decreased expression of SH3PXD2A mRNA28973697
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of SH3PXD2A mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of SH3PXD2A mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of SH3PXD2A mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of SH3PXD2A mRNA28628672
C544151jinfukangjinfukang results in increased expression of SH3PXD2A mRNA27392435
D007854LeadLead affects the expression of SH3PXD2A mRNA28903495
D008628MercuryMercury results in increased expression of SH3PXD2A mRNA16823088
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of SH3PXD2A gene20938992
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of SH3PXD2A mRNA23649840
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of SH3PXD2A mRNA"26251327
C028007nickel monoxidenickel monoxide results in decreased expression of SH3PXD2A mRNA19167457
C016030pantogabpantogab results in decreased expression of SH3PXD2A mRNA17379144
C006253pirinixic acidpirinixic acid results in decreased expression of SH3PXD2A mRNA23811191
D011441PropylthiouracilPropylthiouracil results in decreased expression of SH3PXD2A mRNA24780913
D011794QuercetinQuercetin results in decreased expression of SH3PXD2A mRNA21632981
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of SH3PXD2A mRNA25895662
D012906SmokeSmoke results in decreased expression of SH3PXD2A mRNA21095227
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of SH3PXD2A mRNA20106945
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of SH3PXD2A mRNA21570461|2892240
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in increased expression of SH3PXD2A mRNA25975270
C009495titanium dioxidetitanium dioxide results in decreased expression of SH3PXD2A mRNA23409001
D014212TretinoinTretinoin results in increased expression of SH3PXD2A mRNA23724009|2383079
D014212TretinoinTretinoin results in decreased expression of SH3PXD2A mRNA16604517
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3PXD2A mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of SH3PXD2A mRNA24935251|2627250
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of SH3PXD2A mRNA"26179874
C057693troglitazonetroglitazone results in increased expression of SH3PXD2A mRNA28973697
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SH3PXD2A mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of SH3PXD2A mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of SH3PXD2A mRNA26272509
D014635Valproic AcidValproic Acid results in increased methylation of SH3PXD2A gene29154799
D014635Valproic AcidValproic Acid affects the expression of SH3PXD2A mRNA17963808
C025643vinclozolinvinclozolin results in increased expression of SH3PXD2A mRNA23034163
D024483Vitamin K 3Vitamin K 3 affects the expression of SH3PXD2A mRNA20044591

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0002020protease binding-IEA-  
GO:0005515protein binding-IPI16374509  19755710  20609497  
GO:0005546phosphatidylinositol-4,5-bisphosphate binding-IEA-  
GO:0010314phosphatidylinositol-5-phosphate binding-IEA-  
GO:0016176superoxide-generating NADPH oxidase activator activity-IBA21873635  
GO:0032266phosphatidylinositol-3-phosphate binding-IEA-  
GO:0035091phosphatidylinositol binding-IBA21873635  
GO:0043325phosphatidylinositol-3,4-bisphosphate binding-IEA-  
GO:0070273phosphatidylinositol-4-phosphate binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006801superoxide metabolic process-IBA21873635  
GO:0006801superoxide metabolic process-IDA19755710  
GO:0006801superoxide metabolic process-IMP20609497  
GO:0030198extracellular matrix organization-TAS-  
GO:0043085positive regulation of catalytic activity-IEA-  
GO:0072675osteoclast fusion-IMP22584907  
GO ID GO Term Qualifier Evidence PubMed
GO:0002102podosome-IDA18417249  
GO:0005829cytosol-TAS-  
GO:0030054cell junction-IEA-  
GO:0042995cell projection-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1474244Extracellular matrix organizationTAS
R-HSA-8941237Invadopodia formationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal